Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis.
作者信息
Urits Ivan, Swanson Daniel, Swett Michael C, Patel Anjana, Berardino Kevin, Amgalan Ariunzaya, Berger Amnon A, Kassem Hisham, Kaye Alan D, Viswanath Omar
机构信息
Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center-Harvard Medical School, Boston, MA, USA.
Georgetown University School of Medicine, Washington, DC, USA.
出版信息
Neurol Ther. 2021 Jun;10(1):407. doi: 10.1007/s40120-020-00228-x.
Abstract
摘要
相似文献
1
Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis.《遗传性转甲状腺素蛋白淀粉样变性患者多神经病治疗药物帕替拉韦（ONPATTRO®）综述》勘误
Neurol Ther. 2021 Jun;10(1):407. doi: 10.1007/s40120-020-00228-x.
2
A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis.帕替拉韦（ONPATTRO®）治疗遗传性转甲状腺素蛋白淀粉样变性患者多发性神经病的综述
Neurol Ther. 2020 Dec;9(2):301-315. doi: 10.1007/s40120-020-00208-1. Epub 2020 Aug 12.
3
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病患者用 patisiran 的长期安全性和疗效：一项开放标签扩展研究的 12 个月结果。
Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16.
4
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.一种间接治疗比较研究，评估 patisiran 和 tafamidis 治疗遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病的疗效。
Expert Opin Pharmacother. 2019 Mar;20(4):473-481. doi: 10.1080/14656566.2018.1554648. Epub 2018 Dec 12.
5
Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.遗传性转甲状腺素蛋白介导淀粉样变性多发性神经病中 patisiran 和 inotersen 疗效的间接治疗比较。
Expert Opin Pharmacother. 2021 Jan;22(1):121-129. doi: 10.1080/14656566.2020.1811850. Epub 2020 Sep 7.
6
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.APOLLO 研究中自主神经结局分析，该研究为 III 期临床试验，评估了 RNAi 疗法 patisiran 治疗遗传性转甲状腺素蛋白淀粉样变性患者的疗效。
J Neurol. 2020 Mar;267(3):703-712. doi: 10.1007/s00415-019-09602-8. Epub 2019 Nov 14.
7
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.神经丝轻链作为遗传性转甲状腺素蛋白介导的淀粉样变性的生物标志物。
Neurology. 2021 Jan 19;96(3):e412-e422. doi: 10.1212/WNL.0000000000011090. Epub 2020 Oct 21.
8
Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.帕替拉韦，一种用于治疗遗传性转甲状腺素蛋白介导的淀粉样变性的RNA干扰疗法。
Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033. Epub 2018 Nov 27.
10
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.Patisiran，一种 RNA 干扰治疗药物，与遗传性转甲状腺素淀粉样变心肌病的左心室局部心肌应变的相关性：APOLLO 研究。
JAMA Cardiol. 2019 May 1;4(5):466-472. doi: 10.1001/jamacardio.2019.0849.
引用本文的文献
1
mTORopathies in Epilepsy and Neurodevelopmental Disorders: The Future of Therapeutics and the Role of Gene Editing.癫痫和神经发育障碍中的mTOR病：治疗的未来与基因编辑的作用
Cells. 2025 Apr 30;14(9):662. doi: 10.3390/cells14090662.
2
Approved Nanomedicine against Diseases.已批准的用于治疗疾病的纳米药物。
Pharmaceutics. 2023 Feb 26;15(3):774. doi: 10.3390/pharmaceutics15030774.
3
Potential of siRNA in COVID-19 therapy: Emphasis on design and nanoparticles based delivery.siRNA在COVID-19治疗中的潜力：重点在于设计和基于纳米颗粒的递送。
Front Bioeng Biotechnol. 2023 Feb 6;11:1112755. doi: 10.3389/fbioe.2023.1112755. eCollection 2023.
4
Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment.脂质体和类脂质体纳米颗粒：从抗真菌感染到新冠疫情治疗
Asian J Pharm Sci. 2022 Nov;17(6):817-837. doi: 10.1016/j.ajps.2022.11.002. Epub 2022 Nov 17.
5
Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications.Sox2 通过抑制 TET2 和扰乱 5hmC 和 5mC DNA 修饰来诱导神经胶质瘤细胞干性和肿瘤增殖。
Signal Transduct Target Ther. 2022 Feb 9;7(1):37. doi: 10.1038/s41392-021-00857-0.
6
Toxicology of Nanoparticles in Drug Delivery.纳米颗粒在药物递送中的毒理学
Curr Pathobiol Rep. 2021;9(4):133-144. doi: 10.1007/s40139-021-00227-z. Epub 2021 Nov 24.
Zotero 插件